Nasdaq gnlx.

Genelux Corporation ( NASDAQ: GNLX) has filed to raise $30 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing ...WebGenelux Corp Follow Share $11.87 After Hours: $11.87 (0.00%) 0.00 Closed: Nov 17, 4:02:25 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to SHENGFENG DEVELOPMENT Ltd $11.23 SFWL1.91%... Clinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) said that Lourie S. Zak will join the company as CFO, effective August 28, 2023.Ms. Zak will join Genelux with an extensive background ...Nelly Dodson. November 23, 2023. Business. Genelux Corp (NASDAQ:GNLX)’s traded shares stood at 76372.0 during the last session. At the close of trading, the stock’s price was $11.19, to imply an increase of 7.80% or $0.81 in intraday trading. The GNLX share’s 52-week high remains $40.98, putting it -266.22% down since that peak but still ...

GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...

WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.WebGNLX) stock’s latest price update. Genelux Corp (NASDAQ: GNLX)’s stock price has gone rise by 8.96 in comparison to its previous close of 14.51, however, the company has experienced a -15.41% decrease in its stock price over the last five trading days.In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.

Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...

Source Headline; Genelux (NASDAQ:GNLX) Coverage Initiated by Analysts at HC Wainwright americanbankingnews.com - November 28 at 3:26 AM: HC Wainwright & Co. Initiates Coverage of Genelux (GNLX) with Buy Recommendation msn.com - November 27 at 10:25 PM: Genelux gets fast track status for Olvi-Vec in ovarian cancer msn.com - …WebFintel. Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of ...Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ...28. 8. 2023 ... 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S.GNLX Genelux Corporation Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesWESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...Nov 1, 2023 · Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ...

Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...Genelux | 726 followers on LinkedIn. Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of …add_box. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WebCIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ...

Genelux Corporation (NASDAQ:GNLX) gained 10.5% to $5.02. Latham Group, Inc. (NASDAQ:SWIM) gained 10.2% to $3.7050 following Q4 results. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rose 9.6% to $7.75 ...

GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Uncover the latest insider trading activity for Genelux Corporation (GNLX). Know which insiders are buying and selling along with top shareholders and ownership breakdown. Dashboard Markets Discover Watchlist Portfolios Screener. Genelux Corporation. NasdaqCM:GNLX Stock Report. Mkt Cap: US$317.1m. Add to watchlist.The latest price target for . Genelux (NASDAQ: GNLX) was reported by Maxim Group on September 12, 2023.The analyst firm set a price target for $40.00 expecting GNLX to rise to within 12 months (a ...View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.57.59%. Get the latest Genelux Corp (GNLX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Nov 20, 2023 · The public float for GNLX is 19.35M, and currently, shorts hold a 4.47% of that float. The average trading volume for GNLX on November 20, 2023 was 226.90K shares. GNLX) stock’s latest price update. The stock price of Genelux Corp (NASDAQ: GNLX) has dropped by -9.53 compared to previous close of 13.12. The latest price target for . Dyne Therapeutics (NASDAQ: DYN) was reported by JP Morgan on Wednesday, August 9, 2023.The analyst firm set a price target for 22.00 expecting DYN to rise to within ...

Genelux Corporation (NASDAQ:GNLX) rose 13.1% to $21.38. Legacy Housing Corporation (NASDAQ:LEGH) gained 10.2% to $21.75 following upbeat quarterly results.

WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...Web

Find the latest historical data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...WebGenelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Genelux press release (NASDAQ:GNLX): Q3 GAAP EPS of -$0.20 misses by $0.02. $29.9 million in cash and equivalents. Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage ...Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ... We explain how to buy Genelux Corporation Common Stock stock, compare the best stock trading platforms and use a detailed analysis to learn about (GNLX).WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...Back to GNLX Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...Stock Quote & Chart. NASDAQ: GNLX. $11.90. Nov 30, 2023 4:00 PM EST. Change. +0.2 (+1.71%). Volume. 86,169. Today's Open. $11.79. Previous Close. $11.70.Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from ...Web

Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ...Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.NASDAQ GNLX opened at $11.10 on Monday. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98.Instagram:https://instagram. mt4 stock brokernasdaq rvnchow to trade pre market td ameritradetoyota solid state battery stock Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...WebCompanies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ... slg dividendetf for recession Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ... good options to buy today The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ...Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions.Given GNLX’s positive Phase 2 trial results to-date, my outlook on IPO is a Buy for patient, risk-tolerant life science investors with a long-term hold time frame. ... (NASDAQ:GNLX) was founded ...Web